A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patients With Positive Axillary Lymph Nodes.

Trial Profile

A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patients With Positive Axillary Lymph Nodes.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Dec 2012 Final 10-year results published in the Lancet Oncology.
    • 09 Dec 2010 Final 10-year results will be presented on the 10th of December 2010 at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), according to a sanofi-aventis media release.
    • 08 Dec 2010 Final 10-year results presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS),
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top